Welcome to our dedicated page for 60 degrees pharmaceuticals SEC filings (Ticker: SXTP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
60 Degrees Pharmaceuticals filings document a specialty pharmaceutical issuer with Nasdaq-listed common stock and warrants, emerging-growth-company status and a business focused on medicines for vector-borne disease. Its recent Form 8-K disclosures record material events involving the company’s at-the-market equity offering program, related legal opinions, beneficial-ownership corrections, investor-presentation materials, and clinical development and regulatory strategy updates.
The filing record also covers capital-structure and governance matters, including a one-for-four reverse stock split approved through amendments to the certificate of incorporation, annual meeting voting results and Nasdaq listing-compliance notices. These disclosures frame the company’s formal reporting around ARAKODA, tafenoquine development, equity financing mechanics, security-holder votes and exchange-related requirements.
60 Degrees Pharmaceuticals is asking stockholders to approve several major governance items at its 2026 virtual annual meeting on August 5, 2026. Holders of 2,659,288 shares outstanding as of July 2, 2026 can vote by telephone or mail.
Stockholders will vote on electing five directors, including proposed new director and audit chair Eric Francois, expanding the 2022 Equity Incentive Plan by 800,000 shares to a total reserve of 962,889 shares, and authorizing a reverse stock split at a ratio between 1:5 and 1:10 at the Board’s discretion. Other proposals include ratifying RBSM LLP as auditor, approving a management success fee tied to a change of control or strategic transaction, and allowing adjournment to solicit additional proxies.
60 DEGREES PHARMACEUTICALS, INC. President and CEO Geoffrey S. Dow reported an open-market purchase of Common Stock. On June 12, 2026, he bought 7,350 shares at an average price of $1.3784 per share. After this transaction, he directly owns 24,131 shares of the company’s Common Stock.
60 Degrees Pharmaceuticals is requesting shareholder votes at a virtual Annual Meeting on August 5, 2026 to elect five directors and approve several corporate actions. Key proposals include a request to add 800,000 shares to the 2022 Equity Incentive Plan and a proposal to amend the Certificate of Incorporation to permit a reverse stock split at a ratio between 1:5 and 1:10, as determined by the Board.
The Board recommends voting FOR all proposals, including ratification of RBSM LLP as auditor and approval of a Management Success Fee in connection with a change of control or strategic transaction. Only holders of record as of July 2, 2026 may vote.
60 Degrees Pharmaceuticals, Inc. states that it intends to apply for a Commissioner’s National Priority Review Voucher if data from its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis support submitting a New Drug Application to the U.S. Food and Drug Administration before the end of the first quarter of 2028.
The company explains that this plan reflects its current development and regulatory strategy and emphasizes that expectations about the trial, any future NDA filing, and any voucher application are forward-looking and subject to risks, including clinical outcomes, regulatory interactions, and broader market and risk factors described in its Form 10-K and Form 10-Q filings.
60 Degrees Pharmaceuticals, Inc. director Francois Eric filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing does not list any stock purchases, sales, option exercises, or other transactions, and serves mainly to register his status as a reporting person.
60 Degrees Pharmaceuticals, Inc. reported that its Board of Directors appointed Eric Francois as a director, effective May 13, 2026. He is a veteran healthcare and life sciences financial executive with over 20 years of experience in investment banking, corporate finance, and board roles.
Francois has held senior positions at Raymond James and Credit Suisse, leading equity, debt, and M&A transactions for biotechnology companies. He also previously served as Chief Financial Officer of SCYNEXIS, Inc., where he raised over $300 million in capital and supported the company through FDA approval and commercial launch. He has prior public company board and committee experience and will receive standard non-employee director compensation, with no special arrangements, family relationships, or related-party transactions disclosed.
Knight Therapeutics Inc. filed Amendment No. 3 to its Schedule 13G/A as an exit filing for 60 Degrees Pharmaceuticals, Inc. The amendment states that as of March 31, 2026 the reporting person no longer beneficially owns any shares of the issuer's common stock (CUSIP 83006G104).
The filing reports 0 shares beneficially owned and a 0% ownership percentage, and is signed on May 15, 2026 by Samira Sakhia on behalf of Knight Therapeutics Inc.
60 Degrees Pharmaceuticals reports that CVI Investments, Inc. and Heights Capital Management, Inc. collectively beneficially own 197,911 shares, equal to 7.0% of its common stock. The filing states those shares "consist of Shares issuable upon the exercise of warrants to purchase Shares."
The company had 2,636,788 Shares outstanding as of March 30, 2026. Heights Capital Management is identified as the investment manager to CVI Investments and may exercise voting and dispositive power over the reported shares.
60 Degrees Pharmaceuticals, Inc. reported a net loss attributable to common stockholders of $2.21 million for the quarter ended March 31, 2026, compared with $2.00 million a year earlier. Net product revenue was $162,092, essentially flat versus $163,552 in 2025, while prior-year research revenue of $92,731 did not recur.
Operating expenses rose slightly to $2.17 million, driven mainly by general and administrative costs of $1.89 million, with research and development at $281,464. Cash used in operating activities was $2.74 million, but the company boosted liquidity through at-the-market equity sales, ending the quarter with cash and cash equivalents of $3.34 million.
Management discloses an accumulated deficit of $49.98 million and explicitly states that recurring losses, limited cash runway and funding needs raise substantial doubt about the company’s ability to continue as a going concern for one year from the issuance of these financial statements.
60 Degrees Pharmaceuticals reports beneficial ownership disclosure showing 263,158 shares of Common Stock (approximately 9.1%) attributable collectively to Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC as of the close of business on March 31, 2026.
The filing states the 263,158 shares reflect 131,579 shares issuable upon exercise of each of two warrants held by Intracoastal and is calculated using 2,636,788 shares outstanding as of March 30, 2026. The filing also explains multiple additional warrants contain blocker provisions that limit exercise to avoid exceeding 4.99% ownership; without those blockers, beneficial ownership would be 307,543 shares.